396 related articles for article (PubMed ID: 28118730)
1. Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities - A marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort.
Smaradottir MI; Ritsinger V; Gyberg V; Norhammar A; Näsman P; Mellbin LG
Diab Vasc Dis Res; 2017 Mar; 14(2):69-76. PubMed ID: 28118730
[TBL] [Abstract][Full Text] [Related]
2. Copeptin and insulin-like growth factor binding protein-1 during follow-up after an acute myocardial infarction in patients with type 2 diabetes: A report from the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction 2 cohort.
Smáradóttir MI; Catrina SB; Brismar K; Norhammar A; Gyberg V; Mellbin LG
Diab Vasc Dis Res; 2019 Jan; 16(1):22-27. PubMed ID: 30309264
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of adipokines predict outcome after acute myocardial infarction: A long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort.
Ritsinger V; Brismar K; Malmberg K; Mellbin L; Näsman P; Rydén L; Söderberg S; Tenerz Å; Norhammar A
Diab Vasc Dis Res; 2017 Mar; 14(2):77-87. PubMed ID: 28185529
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of testosterone levels in patients with newly detected glucose abnormalities and acute myocardial infarction.
Wang A; Arver S; Flanagan J; Gyberg V; Näsman P; Ritsinger V; Mellbin LG
Diab Vasc Dis Res; 2018 Nov; 15(6):511-518. PubMed ID: 30280926
[TBL] [Abstract][Full Text] [Related]
5. Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort.
Ritsinger V; Tanoglidi E; Malmberg K; Näsman P; Rydén L; Tenerz Å; Norhammar A
Diab Vasc Dis Res; 2015 Jan; 12(1):23-32. PubMed ID: 25311248
[TBL] [Abstract][Full Text] [Related]
6. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.
Khan SQ; Dhillon OS; O'Brien RJ; Struck J; Quinn PA; Morgenthaler NG; Squire IB; Davies JE; Bergmann A; Ng LL
Circulation; 2007 Apr; 115(16):2103-10. PubMed ID: 17420344
[TBL] [Abstract][Full Text] [Related]
7. Copeptin, insulin-like growth factor binding protein-1 and sitagliptin: A report from the BEta-cell function in Glucose abnormalities and Acute Myocardial Infarction study.
Arnetz L; Hage C; Brismar K; Catrina SB; Norhammar A; Lundman P; Wallander M; Ryden L; Mellbin L
Diab Vasc Dis Res; 2016 Jul; 13(4):307-11. PubMed ID: 27190088
[TBL] [Abstract][Full Text] [Related]
8. Leptin: a predictor of abnormal glucose tolerance and prognosis in patients with myocardial infarction and without previously known Type 2 diabetes.
Wallander M; Söderberg S; Norhammar A
Diabet Med; 2008 Aug; 25(8):949-55. PubMed ID: 18959608
[TBL] [Abstract][Full Text] [Related]
9. Pre-diabetes mellitus newly diagnosed after myocardial infarction adversely affects prognosis in patients without known diabetes.
Chattopadhyay S; George A; John J; Sathyapalan T
Diab Vasc Dis Res; 2019 Nov; 16(6):489-497. PubMed ID: 31044609
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of insulin-like growth factor-binding protein 1 predict outcome after acute myocardial infarction: A long-term follow-up of the glucose tolerance in patients with acute myocardial infarction (GAMI) cohort.
Ritsinger V; Brismar K; Mellbin L; Näsman P; Rydén L; Söderberg S; Norhammar A
Diab Vasc Dis Res; 2018 Sep; 15(5):387-395. PubMed ID: 29992830
[TBL] [Abstract][Full Text] [Related]
11. Use of copeptin and high-sensitive cardiac troponin T for diagnosis and prognosis in patients with diabetes mellitus and suspected acute myocardial infarction.
Zellweger C; Wildi K; Twerenbold R; Reichlin T; Naduvilekoot A; Neuhaus JD; Balmelli C; Gabutti M; Al Afify A; Ballarino P; Jäger C; Druey S; Hillinger P; Haaf P; Vilaplana C; Darbouret B; Ebmeyer S; Rubini Gimenez M; Moehring B; Osswald S; Mueller C
Int J Cardiol; 2015; 190():190-7. PubMed ID: 25920022
[TBL] [Abstract][Full Text] [Related]
12. Abnormal glucose metabolism in acute myocardial infarction: influence on left ventricular function and prognosis.
Høfsten DE; Løgstrup BB; Møller JE; Pellikka PA; Egstrup K
JACC Cardiovasc Imaging; 2009 May; 2(5):592-9. PubMed ID: 19442946
[TBL] [Abstract][Full Text] [Related]
13. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes.
Velho G; Ragot S; El Boustany R; Saulnier PJ; Fraty M; Mohammedi K; Fumeron F; Potier L; Marre M; Hadjadj S; Roussel R
Cardiovasc Diabetol; 2018 Aug; 17(1):110. PubMed ID: 30071874
[TBL] [Abstract][Full Text] [Related]
14. [Impaired glucose tolerance in patients with acute myocardial infarction].
Andersen GØ; Eritsland J; Aasheim A; Neuburger J; Knudsen EC; Mangschau A
Tidsskr Nor Laegeforen; 2006 Sep; 126(17):2264-7. PubMed ID: 16967066
[TBL] [Abstract][Full Text] [Related]
15. Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Rydén L; Brismar K; Morgenthaler NG; Ohrvik J; Catrina SB
Diabetes Care; 2010 Jul; 33(7):1604-6. PubMed ID: 20413521
[TBL] [Abstract][Full Text] [Related]
16. Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys.
Ferrannini G; De Bacquer D; Vynckier P; De Backer G; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Tuomilehto J; Wood D; Rydén L;
Cardiovasc Diabetol; 2021 Feb; 20(1):38. PubMed ID: 33573665
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognosis in patients with acute myocardial infarction and newly detected glucose abnormalities: predictive value of oral glucose tolerance test and HbA1c.
Karayiannides S; Djupsjö C; Kuhl J; Hofman-Bang C; Norhammar A; Holzmann MJ; Lundman P
Cardiovasc Diabetol; 2021 Jun; 20(1):122. PubMed ID: 34126971
[TBL] [Abstract][Full Text] [Related]
18. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction).
Maisel A; Mueller C; Neath SX; Christenson RH; Morgenthaler NG; McCord J; Nowak RM; Vilke G; Daniels LB; Hollander JE; Apple FS; Cannon C; Nagurney JT; Schreiber D; deFilippi C; Hogan C; Diercks DB; Stein JC; Headden G; Limkakeng AT; Anand I; Wu AHB; Papassotiriou J; Hartmann O; Ebmeyer S; Clopton P; Jaffe AS; Peacock WF
J Am Coll Cardiol; 2013 Jul; 62(2):150-160. PubMed ID: 23643595
[TBL] [Abstract][Full Text] [Related]
19. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
Fenske W; Wanner C; Allolio B; Drechsler C; Blouin K; Lilienthal J; Krane V;
J Am Soc Nephrol; 2011 Apr; 22(4):782-90. PubMed ID: 21415158
[TBL] [Abstract][Full Text] [Related]
20. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
Voors AA; von Haehling S; Anker SD; Hillege HL; Struck J; Hartmann O; Bergmann A; Squire I; van Veldhuisen DJ; Dickstein K;
Eur Heart J; 2009 May; 30(10):1187-94. PubMed ID: 19346228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
